ICAP

IMPOWER-022: The Merck Study

A randomized, active-controlled, double-blind clinical study to investigate the safety and efficacy of oral Islatravir, a once-monthly pill as pre-exposure prophylaxis (PrEP) in cisgender women at high risk for HIV-1 infection. Closed to enrollment. In active study follow-up.


Web Links:

https://clinicaltrials.gov/ct2/show/NCT04644029

Status

Past

Locations

Our Approach

Research

Health Challenges

HIV/AIDS